IRIS UniCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.374
AS - Asia 2.123
EU - Europa 2.087
SA - Sud America 467
AF - Africa 62
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.123
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.259
SG - Singapore 1.102
IT - Italia 574
CN - Cina 476
BR - Brasile 393
DE - Germania 371
SE - Svezia 337
FR - Francia 141
IE - Irlanda 135
GB - Regno Unito 116
VN - Vietnam 89
IN - India 87
FI - Finlandia 69
ID - Indonesia 68
RU - Federazione Russa 66
CA - Canada 59
HK - Hong Kong 49
NL - Olanda 43
TR - Turchia 40
PL - Polonia 38
KR - Corea 37
ES - Italia 34
MX - Messico 34
JP - Giappone 32
BD - Bangladesh 31
AR - Argentina 30
UA - Ucraina 29
AT - Austria 21
ZA - Sudafrica 20
CZ - Repubblica Ceca 16
IQ - Iraq 15
IR - Iran 14
PK - Pakistan 14
BE - Belgio 13
MK - Macedonia 13
AE - Emirati Arabi Uniti 12
CO - Colombia 12
EG - Egitto 12
CI - Costa d'Avorio 11
EC - Ecuador 11
CH - Svizzera 10
IL - Israele 10
LT - Lituania 10
RS - Serbia 10
JO - Giordania 7
PA - Panama 7
RO - Romania 7
SA - Arabia Saudita 7
VE - Venezuela 7
PT - Portogallo 6
SK - Slovacchia (Repubblica Slovacca) 5
UZ - Uzbekistan 5
DK - Danimarca 4
MY - Malesia 4
PY - Paraguay 4
AU - Australia 3
BG - Bulgaria 3
CL - Cile 3
DO - Repubblica Dominicana 3
MA - Marocco 3
NZ - Nuova Zelanda 3
PE - Perù 3
PH - Filippine 3
SN - Senegal 3
TN - Tunisia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BT - Bhutan 2
BY - Bielorussia 2
CR - Costa Rica 2
DM - Dominica 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
LV - Lettonia 2
NP - Nepal 2
OM - Oman 2
TH - Thailandia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GL - Groenlandia 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
Totale 7.112
Salva come PNG Salva come JPEG
Città #
Singapore 575
Ashburn 365
Chandler 332
New York 138
Beijing 107
Dublin 107
Rome 107
Hefei 105
Los Angeles 93
Milan 90
Dallas 68
Jakarta 64
Munich 56
Hong Kong 45
São Paulo 42
Frankfurt am Main 40
Boston 39
San Mateo 38
Helsinki 36
Seoul 35
Marseille 33
Moscow 32
Ho Chi Minh City 29
Houston 28
Princeton 28
Kent 27
Tokyo 27
Nuremberg 25
Palermo 24
Buffalo 23
Warsaw 23
Denver 22
Poplar 22
Hanoi 20
Montreal 20
Santa Clara 20
Toronto 20
Ann Arbor 19
Düsseldorf 19
Stockholm 19
Atlanta 18
Chicago 18
Dearborn 18
The Dalles 18
Wilmington 18
Bremen 17
San Francisco 16
Turku 16
Brooklyn 15
Chennai 15
London 15
Mexico City 15
Cattolica 14
Nanjing 14
Nürnberg 14
Pune 14
Amsterdam 13
Augusta 13
Boardman 13
Brno 13
Falkenstein 13
Johannesburg 13
Paris 13
Ankara 12
Brussels 12
Orem 12
Seattle 12
Vienna 12
Abidjan 11
Belo Horizonte 11
Kish 11
Jacksonville 10
Lancaster 10
Manchester 10
Redwood City 10
Rio de Janeiro 10
Salamanca 10
Skopje 10
Bologna 9
Lappeenranta 9
Secaucus 9
Bari 8
Menlo Park 8
Phoenix 8
Shanghai 8
Turin 8
Wroclaw 8
Amman 7
Andover 7
Brasília 7
Charlotte 7
Dhaka 7
Hebei 7
Izmir 7
Mumbai 7
Porto Alegre 7
Washington 7
Woodbridge 7
Bexley 6
Buenos Aires 6
Totale 3.635
Salva come PNG Salva come JPEG
Nome #
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 291
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 282
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 174
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 162
Developmental milestones in type I spinal muscular atrophy 159
Assessing floppy infants: a new module 150
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 140
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 135
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 134
Revised upper limb module for spinal muscular atrophy: Development of a new module 133
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 132
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 132
Predominant distal muscle involvement in spinal muscular atrophy 129
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 123
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 120
Longitudinal assessments in discordant twins with SMA 119
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 117
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 115
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 114
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 113
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 113
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 113
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 112
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 111
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 110
Nusinersen in type 0 spinal muscular atrophy: should we treat? 110
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 110
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 109
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 107
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 106
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 105
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 105
Early treatment of type II SMA slows rate of progression of scoliosis 102
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 102
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 100
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 100
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 100
Developmental milestones in type I spinal muscular atrophy 99
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 93
Clinical Variability in Spinal Muscular Atrophy Type III. 92
Revised upper limb module for spinal muscular atrophy: Development of a new module 91
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 90
Development of an academic disease registry for spinal muscular atrophy 89
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 89
An observational study of functional abilities in infants, children, and adults with type 1 SMA 86
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 82
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 80
Sleep disorders in spinal muscular atrophy 79
Risdiplam in Type 1 Spinal Muscular Atrophy 79
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 79
Longitudinal natural history of type I spinal muscular atrophy: A critical review 78
Long term follow-up of scoliosis progression in type II SMA patients 75
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 75
An observational study of functional abilities in infants, children, and adults with type 1 SMA 73
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 73
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 69
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 68
Revised upper limb module for spinal muscular atrophy: 12 month changes 67
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 67
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 66
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 65
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 65
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 62
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 61
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 59
An observational study of functional abilities in infants, children, and adults with type 1 SMA 58
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 53
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 52
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 44
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 39
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Totale 7.204
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.300
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202152 0 0 0 0 0 9 8 2 9 0 23 1
2021/2022398 13 6 5 72 28 11 9 63 26 19 73 73
2022/20231.150 99 150 66 162 76 144 70 104 164 19 55 41
2023/2024992 34 165 34 88 51 172 152 54 19 49 80 94
2024/20251.684 41 24 108 82 134 92 71 67 249 139 374 303
2025/20262.494 524 135 305 591 872 67 0 0 0 0 0 0
Totale 7.204